200 related articles for article (PubMed ID: 37318030)
1. Different local estrogen therapies for a tailored approach to GSM.
Nappi RE; Tiranini L; Martini E; Bosoni D; Cassani C; Cucinella L
Climacteric; 2023 Aug; 26(4):361-366. PubMed ID: 37318030
[TBL] [Abstract][Full Text] [Related]
2. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
3. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
4. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
5. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
6. The role of hormone therapy in urogenital health after menopause.
Nappi RE; Cucinella L; Martini E; Cassani C
Best Pract Res Clin Endocrinol Metab; 2021 Dec; 35(6):101595. PubMed ID: 34711512
[TBL] [Abstract][Full Text] [Related]
7. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM; Carvalho BM; Moreira MJB; Reis PCA; Colapietro L; Northern J; Batalini F
Clin Breast Cancer; 2023 Dec; 23(8):835-846. PubMed ID: 37806915
[TBL] [Abstract][Full Text] [Related]
8. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
9. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
12. Management of genitourinary syndrome of menopause in breast cancer survivors: An update.
Lubián López DM
World J Clin Oncol; 2022 Feb; 13(2):71-100. PubMed ID: 35316932
[TBL] [Abstract][Full Text] [Related]
13. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.
Mueck AO; Ruan X; Prasauskas V; Grob P; Ortmann O
Climacteric; 2018 Apr; 21(2):140-147. PubMed ID: 29381086
[TBL] [Abstract][Full Text] [Related]
14. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
17. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies.
Castelo-Branco C; Mension E; Torras I; Cebrecos I; Anglès-Acedo S
Climacteric; 2023 Aug; 26(4):296-301. PubMed ID: 36946290
[TBL] [Abstract][Full Text] [Related]
18. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
19. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
